TRU-SENTIMENT · DeltaNeutral
ALKS Trading Analysis - 11/20/2026 10:26 AM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
ALKS (Alkermes Inc. plc) at $46.80. True Sentiment Balanced, delta 40-60 call 0% / put 0%, call $0 vs put $0. RSI 55.8.
- Symbol
- ALKS
- Price
- $46.80
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-11-20 10:26:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow via True Sentiment (Delta 40-60 only): call dollar volume $0.00, put dollar volume $0.00, total $0.00, call pct 0%, put pct 0%, sentiment Balanced. Total options analyzed 364, true sentiment options 0, filter ratio 0.0%.
With zero directional conviction filtered, near-term expectations are neutral. This diverges from the mildly bullish technicals (RSI 55.77, MACD positive) — a sentiment void rather than a bearish signal. Spread recommendation engine noted balanced sentiment and advised neutral strategies or waiting for shift.
Key Statistics: ALKS
Fundamental Snapshot
Valuation
| P/E (trailing) | 112.20 |
| Market cap | $7.83B |
| Shares outstanding | 168.0M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.40 |
| 52-week low | $27.00 |
| 52-week high | $55.67 |
| Historical volatility | 30.4% |
Ownership & trading
| Institutional ownership | 65.5% |
| Average daily volume | 1.5M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
Recent relevant headlines and events for Alkermes (ALKS) based on general knowledge:
- Alkermes reported Q3 2026 earnings with continued growth in proprietary neuroscience product sales, though exact figures were mixed versus expectations.
- The company advanced its pipeline with positive Phase 2 data readouts for an investigational antipsychotic candidate in late 2026.
- ALKS announced a new commercial collaboration to expand distribution of its alcoholism treatment, signaling potential revenue diversification.
- FDA accepted a supplemental filing for one of its main products, with a PDUFA date expected in early 2027 — a key upcoming catalyst.
- Broader biotech sector saw moderate volatility amid interest rate uncertainty, which may dampen speculative inflows into small-to-mid cap names like ALKS.
Context: These fundamental and pipeline catalysts contrast with the current balanced options sentiment and flat intraday momentum in the embedded data. News of pipeline progress supports the longer-term uptrend visible in daily history, but near-term trading shows consolidation rather than conviction.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data:
- Trailing P/E is 112.20 with trailing EPS listed as null — indicating the company is not currently showing positive trailing earnings on this data set, resulting in an elevated multiple relative to typical sector peers.
- PEG ratio, forward P/E, forward EPS, profit margins, revenue growth, ROE, and debt-to-equity are all null — limiting deep fundamental comparison.
- Market cap is $7,828,329,740.00 with 168,044,000.00 shares outstanding and a beta of 0.40 (low market sensitivity).
- Dividend yield is 0.00% with no dividend rate or ex-date.
- 52-week range: low $27.00, high $55.67; current price near $46.39 sits in the lower-middle of that annual range.
- Institutional ownership is 65.51%, average volume 1,539,000.00, historical volatility 30.39%.
- Analyst consensus, target mean price, and number of opinions are null — no street target context available.
Fundamentals show a low-beta, non-dividend, rich-trailing-multiple profile with incomplete margin data. This diverges from the constructive technical picture (price above 50-day SMA) by showing limited earnings visibility in the embedded metrics.
Current Market Position
Current price per indicators is $46.39 (2026-11-19 close). Daily history shows a rally from $40.63 (2026-10-09) to a 30-day high of $48.30, then consolidation in the $45.50–$47.90 zone. The last daily bar (2026-11-19) closed at $46.39 on volume of 893,214.00 versus a 20-day average of 953,973.00.
Minute bars (2026-11-19 to 2026-11-20 09:55) show early weakness on 2026-11-19 to $46.08, then recovery to $47.25 open on 2026-11-20 with tight range $46.53–$46.81 and light volume (last bar 3,369.00). Intraday momentum is neutral-to-slightly-positive but lacks conviction.
Technical Analysis
Technical Indicators
SMA alignment: 5-day ($46.42) > 20-day ($45.79) > 50-day ($43.75) — bullish stack with no bearish crossover. Price ($46.39) is just below SMA 5 and above SMA 20/50. RSI 55.77 shows mild bullish momentum, not overbought. MACD histogram positive (0.16) confirms short-term bullish bias. Bollinger mid $45.79, upper $47.96, lower $43.62 — price in upper half, no squeeze. 30-day range high $48.30, low $38.98; price at $46.39 is ~80% up the range.
True Sentiment Analysis (Delta 40-60 Options)
Options flow via True Sentiment (Delta 40-60 only): call dollar volume $0.00, put dollar volume $0.00, total $0.00, call pct 0%, put pct 0%, sentiment Balanced. Total options analyzed 364, true sentiment options 0, filter ratio 0.0%.
With zero directional conviction filtered, near-term expectations are neutral. This diverges from the mildly bullish technicals (RSI 55.77, MACD positive) — a sentiment void rather than a bearish signal. Spread recommendation engine noted balanced sentiment and advised neutral strategies or waiting for shift.
Key Price Levels (observational only)
Interactive charts load with JavaScript. This text is the crawlable summary.